OncoCyte (OCX) Appoints Peter Gutfreund to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- Wall Street dips as rising Treasury yields outweigh software gains
- Oil prices rise $3 as China suspends fuel exports
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Elevated equity positioning, leverage could challenge stocks in Q4: JPMorgan
- Alphabet shares up in premarket trade after Gemini 4 Argon launch
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Micron Technology (MU) Tops Q4 EPS by $2.26, Offers Guidance
Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022
August 1, 2022 5:00 AM EDTIRVINE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced the appointment of John Peter (JP) Gutfreund as an independent member of its board of directors, effective July 28, 2022.
We welcome JP... More
